Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 377Myelodysplastic Syndromes 159Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 32Myeloproliferative Disorders 23Hematologic Neoplasms 20Neoplasms 19Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, T-Cell, Peripheral 13Primary Myelofibrosis 12Neoplasm, Residual 12Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Leukemia, Myelomonocytic, Acute 10Hodgkin Disease 10Myelodysplastic-Myeloproliferative Diseases 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8Breast Neoplasms 8

Interventions

Peripheral Blood Stem Cell Transplantation 17fludarabine phosphate 16Cyclophosphamide 14Cyclosporine 13Whole-Body Irradiation 11Mycophenolic Acid 11Etoposide 7Methotrexate 6Tacrolimus 5Filgrastim 5Antilymphocyte Serum 5Rituximab 4Radiotherapy 4Prednisone 4Methylprednisolone 4Melphalan 4Busulfan 4Bortezomib 4Alemtuzumab 4Transplantation 3Thiotepa 3Epoetin Alfa 3Dasatinib 3Darbepoetin alfa 3Carboplatin 3thymoglobulin 2ruxolitinib 2nelarabine 2liposomal amphotericin B 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Leukemia, Large Granular Lymphocytic × Azacitidine × Clear all
NCT05141682 2026-03-03

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
11 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT01129180 2013-12-03

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
8 enrolled
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡